JP2003265169A - Biotissue-like structure, method for culturing bone marrow stem cell and culture kit - Google Patents
Biotissue-like structure, method for culturing bone marrow stem cell and culture kitInfo
- Publication number
- JP2003265169A JP2003265169A JP2002076929A JP2002076929A JP2003265169A JP 2003265169 A JP2003265169 A JP 2003265169A JP 2002076929 A JP2002076929 A JP 2002076929A JP 2002076929 A JP2002076929 A JP 2002076929A JP 2003265169 A JP2003265169 A JP 2003265169A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- bone marrow
- marrow stem
- collagen
- support
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001185 bone marrow Anatomy 0.000 title claims abstract description 71
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 65
- 238000000034 method Methods 0.000 title claims abstract description 39
- 238000012258 culturing Methods 0.000 title claims abstract description 33
- 210000004027 cell Anatomy 0.000 claims abstract description 128
- 239000000463 material Substances 0.000 claims abstract description 41
- 229920001059 synthetic polymer Polymers 0.000 claims abstract description 39
- 229920005615 natural polymer Polymers 0.000 claims abstract description 30
- 239000002131 composite material Substances 0.000 claims abstract description 27
- 210000004102 animal cell Anatomy 0.000 claims abstract description 23
- 230000004069 differentiation Effects 0.000 claims abstract description 23
- 238000004113 cell culture Methods 0.000 claims abstract description 11
- 230000002062 proliferating effect Effects 0.000 claims abstract description 9
- 210000001519 tissue Anatomy 0.000 claims description 63
- 239000006143 cell culture medium Substances 0.000 claims description 16
- 239000000470 constituent Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 15
- 230000008602 contraction Effects 0.000 abstract description 7
- 238000002054 transplantation Methods 0.000 abstract description 6
- 230000035755 proliferation Effects 0.000 abstract description 5
- 102000008186 Collagen Human genes 0.000 description 45
- 108010035532 Collagen Proteins 0.000 description 45
- 229920001436 collagen Polymers 0.000 description 45
- 229960005188 collagen Drugs 0.000 description 45
- 239000000515 collagen sponge Substances 0.000 description 22
- 239000000243 solution Substances 0.000 description 22
- 238000004132 cross linking Methods 0.000 description 19
- 238000012136 culture method Methods 0.000 description 12
- 210000000988 bone and bone Anatomy 0.000 description 11
- 230000007547 defect Effects 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 230000017423 tissue regeneration Effects 0.000 description 10
- 239000000835 fiber Substances 0.000 description 9
- 108010022452 Collagen Type I Proteins 0.000 description 8
- 102000012422 Collagen Type I Human genes 0.000 description 8
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 229920000954 Polyglycolide Polymers 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- 239000000512 collagen gel Substances 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 239000004633 polyglycolic acid Substances 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 5
- 229910052782 aluminium Inorganic materials 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 230000018044 dehydration Effects 0.000 description 5
- 238000006297 dehydration reaction Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000001172 regenerating effect Effects 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 210000003969 blast cell Anatomy 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 210000002379 periodontal ligament Anatomy 0.000 description 4
- 210000004872 soft tissue Anatomy 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000004745 nonwoven fabric Substances 0.000 description 3
- 230000003239 periodontal effect Effects 0.000 description 3
- 229920000747 poly(lactic acid) Polymers 0.000 description 3
- 239000004626 polylactic acid Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 108010015046 cell aggregation factors Proteins 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- GXVUZYLYWKWJIM-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanamine Chemical compound NCCOCCN GXVUZYLYWKWJIM-UHFFFAOYSA-N 0.000 description 1
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical group O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- KYWKJKVQLGANBH-UHFFFAOYSA-N 3-butyl-1-methyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(CCCC)C2=C1NC=N2 KYWKJKVQLGANBH-UHFFFAOYSA-N 0.000 description 1
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 102100022210 COX assembly mitochondrial protein 2 homolog Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102100033779 Collagen alpha-4(IV) chain Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010022355 Fibroins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000900446 Homo sapiens COX assembly mitochondrial protein 2 homolog Proteins 0.000 description 1
- 101000710870 Homo sapiens Collagen alpha-4(IV) chain Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- -1 L-ascorbic acid) Chemical compound 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 101100219325 Phaseolus vulgaris BA13 gene Proteins 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 108010045569 atelocollagen Proteins 0.000 description 1
- 229920000704 biodegradable plastic Polymers 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000003074 dental pulp Anatomy 0.000 description 1
- 210000001968 dental pulp cell Anatomy 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 210000003275 diaphysis Anatomy 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002682 general surgery Methods 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- LFKYBJLFJOOKAE-UHFFFAOYSA-N imidazol-2-ylidenemethanone Chemical compound O=C=C1N=CC=N1 LFKYBJLFJOOKAE-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007762 localization of cell Effects 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000012335 pathological evaluation Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000003863 physical function Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000000622 polydioxanone Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 210000001581 salivary duct Anatomy 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、生体組織や臓器の
欠損部等の再生や、生体組織や臓器に対する薬理学、組
織学、生理学または病理学的な検査をin−vitro
培養系で行うために用いることのできる、生体組織様構
造体に関する。また、本発明は、上述のような生体組織
様構造体を得ることのできる培養方法であって、細胞の
足場となる支持体上で骨髄幹細胞を増殖、分化させる骨
髄幹細胞の培養方法、さらには、この培養方法に用いる
ことのできる培養用キットに関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to the regeneration of defective parts of living tissues and organs, and in-vitro pharmacological, histological, physiological and pathological examinations of living tissues and organs.
The present invention relates to a biological tissue-like structure that can be used to perform in a culture system. Further, the present invention is a culture method capable of obtaining a biological tissue-like structure as described above, wherein the bone marrow stem cells are proliferated and differentiated on a support serving as a scaffold for cells, and further, , A culture kit that can be used in this culture method.
【0002】[0002]
【従来の技術】近年、ティシュエンジニアリング技術を
基礎とした生体組織の欠損部の再生が熱心に試みられて
いる。1つの試みとして、増殖分化ポテンシャルの高い
幹細胞を用いることが考えられ、細胞培養技術を用いて
種々の条件で幹細胞を増殖、分化させることは、現実に
かなり可能となってきている。しかしながら、欠損部に
細胞を与えるだけでは組織の再生は実現できず、これを
可能とするためには、幹細胞を適当な足場材料とともに
培養し、3次元の生体組織様構造体を得ることが必要と
なる。また、これらの構造体は、in−vitroにお
ける薬理学、組織学、生理学または病理学的な評価のた
めの材料としても利用できる。なかでも、骨や軟骨とい
った骨系組織等の硬組織部分や、骨髄、皮膚、神経、脂
肪および筋肉組織等の軟組織部分の欠損部を修復したり
再生することを目的として、骨髄幹細胞を増殖、分化さ
せ、利用する培養が注目されている。このような細胞培
養、組織培養においては、使用する培養液や血清および
ホルモン剤等の各種添加剤成分の種類を選択することは
当然重要となるが、細胞の足場となる支持体材料として
どのような物性および機能を有するものを用いればよい
かということが特に重要であるとして、様々な研究開発
がなされている。2. Description of the Related Art In recent years, attempts have been enthusiastically attempted to reproduce a defect in a living tissue based on tissue engineering technology. As one attempt, it is considered to use stem cells having a high proliferation and differentiation potential, and it has become quite possible actually to proliferate and differentiate stem cells under various conditions using cell culture technology. However, tissue regeneration cannot be realized simply by giving cells to the defect, and in order to enable this, it is necessary to culture stem cells with an appropriate scaffold material to obtain a three-dimensional biological tissue-like structure. Becomes Further, these structures can be used as a material for pharmacological, histological, physiological or pathological evaluation in vitro. Among them, bone marrow stem cells are proliferated for the purpose of repairing or regenerating hard tissue parts such as bone-based tissues such as bone and cartilage, and defects of soft tissue parts such as bone marrow, skin, nerve, fat and muscle tissues. Cultures that have been differentiated and used have attracted attention. In such cell culture and tissue culture, it is naturally important to select the type of culture medium and various additive components such as serum and hormonal agents, but how should it be used as a scaffold for cells? Various researches and developments have been made on the basis that it is particularly important to use the one having various physical properties and functions.
【0003】上記細胞の足場となる支持体材料として
は、1)細胞との親和性を有すること、2)組織再生に
要する期間中十分な力学的強度が保持できること、3)
生体分解吸収性を有し、組織再生の経過を妨げないよう
にその進行に応じて速やかに分解消失させうること、
4)細胞が入り易くし、かつ入り込んだ細胞に対する酸
素や栄養の供給を可能にするために多孔質であること、
等が要求されると考えられている。そして、このような
要求を満たす支持体材料を使用して骨髄幹細胞を培養す
れば、培養中の足場の収縮がなく、細胞に対する酸素や
栄養物の供給にも優れるため、より効率の良い細胞の増
殖、分化が期待され、また、最終的に得られる細胞と足
場材料との複合体も縮むことがないため、初期の設計ど
おりの移植用材料が得られるなどの優れた効果が期待で
きると考えられる。As a support material for the scaffolding of the cells, 1) it has affinity with cells, 2) it can maintain sufficient mechanical strength during the period required for tissue regeneration, and 3).
It has biodegradability and absorbability, and can be rapidly decomposed and eliminated according to its progress so as not to interfere with the progress of tissue regeneration.
4) It is porous to make it easy for cells to enter and to supply oxygen and nutrients to the cells that have entered,
Etc. are considered to be required. When bone marrow stem cells are cultivated using a support material satisfying such requirements, there is no contraction of the scaffold during culturing, and oxygen and nutrients are excellently supplied to the cells. Proliferation and differentiation are expected, and since the finally obtained composite of cells and scaffold material does not shrink, it is expected that excellent effects such as obtaining transplant material as originally designed can be expected. To be
【0004】上記足場となる支持体材料としては、従来
から、天然高分子であるコラーゲンを用いたスポンジ状
成形体が知られているが、力学的強度が低いという欠点
があり、実際に生体内に埋入した場合あるいは細胞接種
のため細胞懸濁液に浸漬した場合、その形状が維持でき
ないといった問題があった。一方、力学的強度の問題を
解決する生体組織再生用材料として、例えば、ポリ乳
酸、ポリグリコール酸、あるいはこれらの共重合体、も
しくはこれらとε−カプロラクトンとの共重合体等の生
体分解性の合成高分子を用いたスポンジ状成形体や不織
布等が提案されているが、生体分解性合成高分子のみか
らなる材料では、コラーゲンに比べて細胞との親和性に
劣ると同時に、その分解消失に要する時間が長く、材料
の残存が生体組織の再生の妨げになるといった問題があ
った。このように、コラーゲンもしくは生体分解性合成
高分子を単独に用いた材料では、上記1)〜3)を同時
に満足させることは難しかった。As a support material for the scaffold, a sponge-like molded article using collagen, which is a natural polymer, has been conventionally known, but it has a drawback of low mechanical strength and is actually used in vivo. There was a problem that the shape could not be maintained when it was embedded in the cell or immersed in the cell suspension for cell inoculation. On the other hand, as a material for regenerating a biological tissue that solves the problem of mechanical strength, for example, polylactic acid, polyglycolic acid, or a copolymer thereof, or a biodegradable material such as a copolymer of these and ε-caprolactone is used. Although sponge-like moldings and non-woven fabrics using synthetic polymers have been proposed, materials consisting only of biodegradable synthetic polymers have poor affinity for cells as compared with collagen, and at the same time, their degradation disappears. There is a problem that it takes a long time and the remaining material hinders the regeneration of the living tissue. As described above, it was difficult to simultaneously satisfy the above 1) to 3) with a material using collagen or biodegradable synthetic polymer alone.
【0005】そこで、両者の短所を補う1つの方法とし
て、近年、コラーゲンと生体分解性合成高分子との複合
材料の開発がなされている。例えば、特開平7−236
688号公報では、コラーゲンからなるスポンジ材料の
少なくとも一部を生体分解性プラスチックで被覆した複
合材料が提案されている。しかし、この複合材料は、そ
の表面に合成高分子が存在するため、力学的強度には優
れるものの、生体適合性については依然として低く、改
良の余地があるものであった。他方、「人工臓器」29
巻2号,463−467(2000年)には、乳酸/グ
リコール酸共重合体から作製したスポンジをコラーゲン
溶液に浸漬した後、凍結乾燥して得られる複合材料が報
告されている。しかし、このようにして得られた複合材
料は、コラーゲンに対する合成高分子の比率が高く、細
胞との親和性という点ではやはり十分に満足のいく性能
は得られず、しかも材料が体内で分解吸収されるのに要
する時間も組織再生の観点からは長すぎるといった問題
があった。Therefore, as one method for compensating for the disadvantages of both, a composite material of collagen and a biodegradable synthetic polymer has been developed in recent years. For example, JP-A-7-236
Japanese Patent No. 688 proposes a composite material in which at least a part of collagen sponge material is coated with biodegradable plastic. However, since this composite material has a synthetic polymer on its surface, it has excellent mechanical strength, but its biocompatibility is still low and there is room for improvement. On the other hand, "artificial organs" 29
Volume 2, 463-467 (2000) reports a composite material obtained by immersing a sponge made of a lactic acid / glycolic acid copolymer in a collagen solution and then freeze-drying it. However, the composite material obtained in this way has a high ratio of synthetic polymer to collagen, and it is still not sufficiently satisfactory in terms of affinity with cells, and the material is decomposed and absorbed in the body. There was a problem that the time required for the treatment was too long from the viewpoint of tissue regeneration.
【0006】[0006]
【発明が解決しようとする課題】そこで、本発明の解決
しようとする課題は、培養中の足場の収縮がなく、細胞
に対する酸素や栄養物の供給にも優れるため、より効率
の良い細胞の増殖、分化が期待され、また、最終的に得
られる細胞と足場材料との複合体も縮むことがないた
め、初期の設計どおりの移植用材料が得られる等の優れ
た効果を得ることのできる骨髄幹細胞の培養方法、この
培養方法に用いることのできる培養用キット、および、
生体組織様構造物を提供することを目的とする。Therefore, the problem to be solved by the present invention is that there is no contraction of the scaffold during culturing and the supply of oxygen and nutrients to the cells is excellent, so that more efficient cell growth is possible. , Bone marrow that is expected to undergo differentiation, and does not shrink the finally obtained complex of cells and scaffolding material, so that it is possible to obtain excellent effects such as obtaining the transplantation material as originally designed. Stem cell culture method, culture kit that can be used in this culture method, and
It is intended to provide a biological tissue-like structure.
【0007】[0007]
【課題を解決するための手段】本発明者は、上記課題を
解決するため鋭意検討を行った。その結果、骨髄幹細胞
の培養方法における支持体材料として、合成高分子の含
有率が低く抑えられ且つ効果的に力学的強度を保持した
ものを用いればよいのではないかと考え、かかる知見に
基づき試行錯誤および検討を繰り返したところ、コラー
ゲン等の天然高分子と生体分解吸収性合成高分子との複
合材料であって、生体分解吸収性合成高分子を繊維状の
形態で存在させるとともに天然高分子を架橋させてなる
支持体材料を必須要素として用いれば、上記課題を一挙
に解決し得ることを確認し、本発明を完成するに至っ
た。Means for Solving the Problems The inventors of the present invention have made extensive studies to solve the above problems. As a result, we thought that it would be good to use a support material in the method of culturing bone marrow stem cells that has a low synthetic polymer content and that effectively retains mechanical strength. After repeated mistakes and studies, it was found that it was a composite material of a natural polymer such as collagen and a biodegradable and absorbable synthetic polymer. It was confirmed that the above problems can be solved at once by using a crosslinked support material as an essential element, and the present invention has been completed.
【0008】すなわち、本発明にかかる生体組織様構造
体は、架橋した天然高分子からなるスポンジ中に生体分
解性合成高分子が繊維状の形態で存在してなる複合材料
を必須材料として構成された支持体に、動物細胞培養液
が含まれ、かつ、骨髄幹細胞、および/または、骨髄幹
細胞から分化した生体組織細胞、および/または、前記
分化過程における中間細胞が支持されてなることを特徴
とする。また、本発明にかかる骨髄幹細胞の培養方法
は、架橋した天然高分子からなるスポンジ中に生体分解
性合成高分子が繊維状の形態で存在してなる複合材料を
必須材料として構成された支持体と動物細胞培養液とを
用い、前記支持体上で骨髄幹細胞を増殖および/または
分化させることを特徴とする。That is, the biological tissue-like structure according to the present invention is constituted by using a composite material in which a biodegradable synthetic polymer is present in a fibrous form in a sponge composed of a crosslinked natural polymer as an essential material. The support contains an animal cell culture medium, and supports bone marrow stem cells and / or living tissue cells differentiated from the bone marrow stem cells and / or intermediate cells in the differentiation process. To do. In addition, the method for culturing bone marrow stem cells according to the present invention is a support composed essentially of a composite material in which a biodegradable synthetic polymer is present in a fibrous form in a sponge composed of a crosslinked natural polymer. And an animal cell culture medium are used to grow and / or differentiate bone marrow stem cells on the support.
【0009】また、本発明にかかる培養用キットは、架
橋した天然高分子からなるスポンジ中に生体分解性合成
高分子が繊維状の形態で存在してなる複合材料を必須材
料として構成された支持体、骨髄幹細胞、および/また
は、骨髄幹細胞から分化した生体組織細胞、および/ま
たは、前記分化過程における中間細胞、ならびに、動物
細胞培養液をそれぞれ独立に構成要素として含むことを
特徴とする。In addition, the culture kit according to the present invention is a support composed essentially of a composite material in which a biodegradable synthetic polymer is present in a fibrous form in a sponge composed of a crosslinked natural polymer. It is characterized in that the body, the bone marrow stem cells, and / or the living tissue cells differentiated from the bone marrow stem cells, and / or the intermediate cells in the differentiation process, and the animal cell culture medium are independently contained as constituent elements.
【0010】[0010]
【発明の実施の形態】以下、本発明について詳しく説明
するが、本発明の範囲はこれらの説明に拘束されること
はなく、以下の例示以外についても、本発明の趣旨を損
なわない範囲で適宜実施し得る。本発明にかかる骨髄幹
細胞の培養方法(以下、本発明の培養方法と称すること
がある。)は、架橋した天然高分子からなるスポンジ中
に生体分解性合成高分子が繊維状の形態で存在してなる
複合材料を必須材料として構成された支持体と動物細胞
培養液とを用い、前記支持体上で骨髄幹細胞を増殖およ
び/または分化させる培養方法である。BEST MODE FOR CARRYING OUT THE INVENTION The present invention will be described in detail below. However, the scope of the present invention is not restricted by these explanations, and other than the following examples, the scope of the present invention is not impaired. It can be carried out. The method for culturing bone marrow stem cells according to the present invention (hereinafter sometimes referred to as the culturing method of the present invention) is such that a biodegradable synthetic polymer is present in a fibrous form in a sponge composed of a crosslinked natural polymer. This is a culture method in which a bone marrow stem cell is proliferated and / or differentiated on the support using a support and an animal cell culture solution which are composed of the composite material as an essential material.
【0011】本発明の培養方法においては、支持体は、
生体組織再生用としても用いることのできる上記複合材
料を必須要素とする。上記複合材料は、特に限定はされ
ないが、具体的には、天然高分子の溶液中に繊維状の生
体分解吸収性合成高分子を含浸させた状態で凍結乾燥を
行い、その後架橋処理を施して天然高分子を架橋するこ
とにより得ることができる。天然高分子としては、特に
限定はされないが、具体的には、例えば、コラーゲン、
ゼラチン、フィブリン、グルテン、フィブロイン等のタ
ンパク質およびこれらの誘導体;ポリアミノ酸およびこ
れらの誘導体;キチン、キトサン、ヒアルロン酸、アル
ギン酸、デンプン、デキストラン等の多糖およびこれら
の誘導体;これらの2種以上からなる混合物および化学
結合により作製された複合体;等が挙げられる。なお、
天然高分子は1種のみを用いてもよいし、2種以上を併
用してもよい。In the culture method of the present invention, the support is
The above-mentioned composite material that can also be used for regeneration of biological tissue is an essential element. The above-mentioned composite material is not particularly limited, but specifically, lyophilization is performed in a state where a fibrous biodegradable and absorbable synthetic polymer is impregnated in a solution of a natural polymer, and then a crosslinking treatment is performed. It can be obtained by crosslinking a natural polymer. The natural polymer is not particularly limited, but specifically, for example, collagen,
Proteins such as gelatin, fibrin, gluten, fibroin and their derivatives; polyamino acids and their derivatives; polysaccharides such as chitin, chitosan, hyaluronic acid, alginic acid, starch, dextran and their derivatives; mixtures of two or more thereof. And a complex formed by a chemical bond; and the like. In addition,
Only one natural polymer may be used, or two or more natural polymers may be used in combination.
【0012】天然高分子としては、上記列挙した中でも
コラーゲンがより好ましい。コラーゲンとしては、特に
限定はされるわけではなく、動物の骨や皮等を原料とし
て得られる従来公知のコラーゲンであればよいが、具体
的には、例えば、酸可溶化コラーゲン、酵素可溶化コラ
ーゲン、アルカリ可溶化コラーゲン、酸素可溶性コラー
ゲン等の可溶性コラーゲン、または、該可溶化コラーゲ
ンの化学修飾コラーゲンや、該可溶化コラーゲンからコ
ラーゲン繊維を再生させた再生コラーゲン等を好ましく
挙げることができる。上記可溶性コラーゲンとしては、
I型コラーゲンがより好ましい。該I型コラーゲンは、
骨、腱、象牙質などに認められるコラーゲンと一致する
ため、移植部位への置換性に優れており好ましい。さら
に該I型コラーゲンのなかでも、アテロコラーゲンは、
生体為害性の原因となる分子末端のテロペプタイドが酵
素処理のより一部または全部除去されているので、生体
に対して抗原性をほとんどまたは全く有しないため好ま
しい。より具体的には、例えば、豚皮由来I型コラーゲ
ン、豚腱由来I型コラーゲン、牛鼻軟骨由来II型コラー
ゲン、魚から抽出したI型コラーゲン、遺伝子組換え型
のコラーゲンあるいはこれらの混合物等が挙げられる。Among the natural polymers listed above, collagen is more preferred as the natural polymer. The collagen is not particularly limited, and may be any conventionally known collagen obtained from animal bones or skins as raw materials, and specifically, for example, acid-solubilized collagen, enzyme-solubilized collagen Preferable examples include soluble collagen such as alkali-solubilized collagen and oxygen-soluble collagen, chemically modified collagen of the solubilized collagen, and regenerated collagen obtained by regenerating collagen fibers from the solubilized collagen. As the soluble collagen,
Type I collagen is more preferred. The type I collagen is
Since it is the same as collagen found in bone, tendon, dentin, etc., it is excellent in the ability to be replaced at the transplant site, which is preferable. Among the type I collagen, atelocollagen is
Since the telopeptide at the terminal of the molecule that causes bio-toxicity is partially or wholly removed by the enzymatic treatment, it has little or no antigenicity to the living body, which is preferable. More specifically, for example, pig skin-derived type I collagen, pig tendon-derived type I collagen, bovine nose cartilage-derived type II collagen, fish type I collagen, gene recombinant collagen, or a mixture thereof and the like. To be
【0013】前述のように、上記複合材料を得る場合
は、天然高分子は一旦溶液状にして取り扱うが、天然高
分子としてコラーゲンを用いる場合、コラーゲン溶液の
濃度としては、特に限定はされないが、具体的には、
0.05〜10重量%とすることが好ましく、0.3〜
2重量%とすることがより好ましい。コラーゲン溶液の
濃度が、0.05重量%未満の場合は、コラーゲンの量
が少なすぎて、スポンジ状の構造を十分に作製できない
おそれがあり、10重量%を超える場合は、水溶液の粘
度が高くなり、該スポンジを作製する際の取り扱いが困
難となるおそれがある。As described above, when the above-mentioned composite material is obtained, the natural polymer is once treated in the form of a solution. When collagen is used as the natural polymer, the concentration of the collagen solution is not particularly limited. In particular,
It is preferably 0.05 to 10% by weight, and 0.3 to
More preferably, it is 2% by weight. If the concentration of the collagen solution is less than 0.05% by weight, the amount of collagen may be too small to form a sponge-like structure sufficiently, and if it exceeds 10% by weight, the viscosity of the aqueous solution may be high. Therefore, it may be difficult to handle the sponge when it is produced.
【0014】また、天然高分子としてコラーゲンを用い
る場合、前記コラーゲン溶液には、効果的に発泡させて
得られるコラーゲンスポンジのポアサイズを最適な範囲
にする目的で、水と相溶しない性質をもつ有機溶媒を添
加することができる。このような有機溶媒としては、特
に限定はされないが、具体的には、例えば、クロロホル
ム、四塩化炭素、塩化メチレン等のハロゲン化炭化水
素;酢酸エチル、プロピオン酸エチル等のエステル類;
ベンゼン、トルエン等の芳香族炭化水素類;ヘキサン、
シクロヘキサン等の脂肪族炭化水素類;ジエチルエーテ
ル、ジイソプロピルエーテル等のエーテル類;等が挙げ
られる。これらは1種のみを用いても、2種以上を併用
してもよい。なお、これら有機溶媒を添加する場合、そ
の効果を十分に発揮させるためには、添加した後の有機
溶媒濃度を2重量%以上となるようにすることが好まし
く、より好ましくは2〜20重量%、さらにより好まし
くは2〜10重量%である。When collagen is used as a natural polymer, the collagen solution has an organic property that is incompatible with water for the purpose of adjusting the pore size of the collagen sponge obtained by effective foaming to an optimum range. A solvent can be added. The organic solvent is not particularly limited, but specifically, for example, halogenated hydrocarbons such as chloroform, carbon tetrachloride, methylene chloride; esters such as ethyl acetate, ethyl propionate;
Aromatic hydrocarbons such as benzene and toluene; hexane,
Aliphatic hydrocarbons such as cyclohexane; ethers such as diethyl ether and diisopropyl ether; and the like. These may be used alone or in combination of two or more. In addition, when these organic solvents are added, in order to sufficiently bring out the effect, it is preferable that the concentration of the organic solvent after addition is 2% by weight or more, and more preferably 2 to 20% by weight. , And even more preferably 2 to 10% by weight.
【0015】さらに、天然高分子としてコラーゲンを用
いる場合、前記コラーゲン溶液には、コラーゲンスポン
ジの製造において従来から用いられている各種添加剤
を、本発明の効果を損なわない範囲で、必要に応じて添
加しておいてもよい。具体的には、例えば、ムコ多糖
類、細胞接着因子、細胞増殖因子、サイトカイン、ケモ
カイン等、あるいはこれらの物質の有する生理活性をも
つタンパク質やペプチド等を添加しておくことにより、
生体適合性をより向上させることができる。生体分解性
合成高分子としては、特に限定はされないが、具体的に
は、例えば、ポリグリコール酸、ポリ乳酸、ポリ−ε―
カプロラクトン、ポリジオキサノン、ポリ−β−リンゴ
酸、ポリオルソエステル、ポリジアミノホスファゼン、
およびこれらの共重合体等が挙げられる。これらの中で
も特に、一般的な組織再生の期間に適した生体分解性を
有する点から、ポリグリコール酸、ポリ乳酸、ポリ−ε
―カプロラクトン、あるいはこれらの共重合体が好まし
い。なお、生体分解性合成高分子は1種のみを用いて
も、2種以上を併用してもよい。Further, when collagen is used as a natural polymer, various additives conventionally used in the production of collagen sponge are added to the collagen solution as needed, as long as the effects of the present invention are not impaired. You may add it. Specifically, for example, by adding mucopolysaccharides, cell adhesion factors, cell growth factors, cytokines, chemokines, etc., or proteins or peptides having physiological activity possessed by these substances,
The biocompatibility can be further improved. The biodegradable synthetic polymer is not particularly limited, but specifically, for example, polyglycolic acid, polylactic acid, poly-ε-
Caprolactone, polydioxanone, poly-β-malic acid, polyorthoester, polydiaminophosphazene,
And copolymers thereof and the like. Among these, polyglycolic acid, polylactic acid, and poly-ε are particularly preferable because they have biodegradability suitable for the period of general tissue regeneration.
-Caprolactone or a copolymer thereof is preferable. The biodegradable synthetic polymer may be used alone or in combination of two or more.
【0016】生体分解性合成高分子は、繊維状になって
いることが重要である。生体分解性合成高分子を繊維状
の形態で存在させることにより、少ない含有量で十分な
力学的強度を保持させることができる。詳しくは、該繊
維は、長繊維であっても短繊維であってもよいが、例え
ば不織布をほぐした状態のように、十分に絡まりあって
いることが好ましい。また、その繊維径も、特に限定さ
れず、具体的には、1〜100μm径のものを好ましく
用いることができる。生体分解性合成高分子の含有量に
ついては、生体分解性合成高分子/天然高分子(乾燥重
量比)=0.01〜5となるようにすることが好まし
く、より好ましくは0.05〜3、さらにより好ましく
は0.1〜1である。上記重量比が0.01未満である
と、コラーゲンスポンジの体積を保つだけの力学的強度
が得られないおそれがあり、5を超える場合は、生体分
解性合成高分子がコラーゲンスポンジ内に多く露出し、
該スポンジのみの場合よりも細胞親和性に劣るものとな
るおそれがある。前述のように、生体分解性合成高分子
は繊維状であるので、上記範囲のように生体分解性合成
高分子の含有量が少なくても十分な力学的強度を保持さ
せることができる。そして、生体分解性合成高分子の含
有量が少ないことにより、優れた細胞との親和性を発現
すると同時に、組織再生後に速やかに分解消失させるこ
とができる。天然高分子としてコラーゲンを用いる場合
は、生体分解性合成高分子は、前記コラーゲンに対して
(コラーゲン溶液(前記有機溶媒や各種添加剤を添加す
る前の状態)を用いる場合は含有コラーゲンの重量に対
して)重量比(乾燥重量比)で、0.01〜5とするこ
とが好ましく、より好ましくは0.1〜1である。It is important that the biodegradable synthetic polymer is fibrous. By allowing the biodegradable synthetic polymer to exist in a fibrous form, it is possible to maintain sufficient mechanical strength with a small content. Specifically, the fibers may be long fibers or short fibers, but it is preferable that the fibers are sufficiently entangled with each other, for example, in a state in which a nonwoven fabric is loosened. The fiber diameter is also not particularly limited, and specifically, a fiber diameter of 1 to 100 μm can be preferably used. Regarding the content of the biodegradable synthetic polymer, it is preferable that the biodegradable synthetic polymer / natural polymer (dry weight ratio) = 0.01 to 5, and more preferably 0.05 to 3 , And even more preferably 0.1 to 1. If the above weight ratio is less than 0.01, mechanical strength sufficient to maintain the volume of the collagen sponge may not be obtained, and if it exceeds 5, a large amount of biodegradable synthetic polymer is exposed in the collagen sponge. Then
The cell affinity may be lower than that of the sponge alone. As described above, since the biodegradable synthetic polymer is fibrous, sufficient mechanical strength can be maintained even if the content of the biodegradable synthetic polymer is small as in the above range. Since the content of the biodegradable synthetic polymer is low, excellent affinity with cells can be expressed, and at the same time, the biodegradable synthetic polymer can be rapidly decomposed and eliminated after tissue regeneration. When collagen is used as the natural polymer, the biodegradable synthetic polymer is added to the collagen (when the collagen solution (the state before adding the organic solvent and various additives) is used, the amount of the collagen contained is equal to that of the collagen). The weight ratio (dry weight ratio) is preferably 0.01 to 5, and more preferably 0.1 to 1.
【0017】凍結乾燥は、特に限定はされないが、具体
的には、例えば、繊維状の生体分解性合成高分子を入れ
た容器内に天然高分子の溶液を加え、生体分解性合成高
分子繊維を含浸させた状態にして行えばよい。このと
き、容器に加える天然高分子の溶液は、通常のホモジナ
イザー等を用いて十分には発泡させておくことが好まし
い。凍結乾燥の方法については、常法に従って行えばよ
いが、具体的には、例えば、凍結の際の温度は−196
〜−4℃とすることが好ましく、より好ましくは−10
0〜−4℃、さらにより好ましくは−90〜−10℃で
ある。上記凍結乾燥の際の温度が、−196℃未満の場
合は、得られたスポンジの孔径が小さく、細胞がスポン
ジ内に侵入して増殖、分化することができないおそれが
あり、−4℃を超える場合は、スポンジの孔径が大きく
なりすぎて細胞がスポンジ内に安定して存在できない、
また、生体分解性高分子の繊維がスポンジ孔内に露出す
ることで細胞親和性が損なわれるおそれがある。なお、
スポンジ内へ細胞が侵入しやすく、また、細胞がスポン
ジ内で安定して存在し増殖や分化することができる点
で、例えば、コラーゲンスポンジの孔径は、80〜30
0μmであることが好ましい。Freeze-drying is not particularly limited, but specifically, for example, a solution of a natural polymer is added to a container containing a fibrous biodegradable synthetic polymer, and the biodegradable synthetic polymer fiber is added. May be impregnated. At this time, the solution of the natural polymer added to the container is preferably sufficiently foamed by using an ordinary homogenizer or the like. The freeze-drying method may be carried out according to a conventional method. Specifically, for example, the temperature at the time of freezing is -196.
To -4 ° C is preferable, and -10 is more preferable.
0 to -4 ° C, and even more preferably -90 to -10 ° C. If the temperature during freeze-drying is less than -196 ° C, the resulting sponge has a small pore size, and cells may not penetrate into the sponge to proliferate or differentiate. In this case, the pore size of the sponge becomes too large and cells cannot stably exist in the sponge.
In addition, exposure of the biodegradable polymer fibers into the sponge pores may impair the cell affinity. In addition,
For example, the collagen sponge has a pore size of 80 to 30 because cells easily enter the sponge and the cells can stably exist and proliferate and differentiate in the sponge.
It is preferably 0 μm.
【0018】凍結乾燥により得られたスポンジには、続
いて架橋処理を施すことが重要である。すなわち、この
架橋処理によりコラーゲン等の天然高分子を架橋する。
架橋した天然高分子とすることにより、スポンジの生体
分解性をコントロールし、生体分解性合成高分子の含有
量が少なくても十分な力学的強度を保持させることがで
きる。架橋処理の方法については、特に限定はされない
が、具体的には、例えば、従来公知の化学架橋法、真空
下での熱脱水架橋法、紫外線照射による架橋法等を採用
すればよい。It is important that the sponge obtained by freeze-drying is subsequently subjected to a crosslinking treatment. That is, natural polymers such as collagen are crosslinked by this crosslinking treatment.
By using a crosslinked natural polymer, the biodegradability of the sponge can be controlled and sufficient mechanical strength can be maintained even if the content of the biodegradable synthetic polymer is low. The method of the cross-linking treatment is not particularly limited, but specifically, a conventionally known chemical cross-linking method, a thermal dehydration cross-linking method under vacuum, a cross-linking method by ultraviolet irradiation, or the like may be adopted.
【0019】化学架橋を行う場合は、グルタルアルデヒ
ド、カルボジイミド、カルボニルイミダゾール、ジエポ
キシ化合物、ジ酸無水物、エピクロルヒドリン等の架橋
剤を用いればよく、公知の架橋方法を用いて行えばよ
い。真空下で熱脱水架橋させる場合は、特に限定はされ
ないが、具体的には、架橋温度は100〜170℃であ
ることが好ましく、より好ましくは110〜160℃、
さらにより好ましくは120〜160℃であり、架橋に
要する時間は2〜120時間であることが好ましく、よ
り好ましくは3〜100時間、さらにより好ましくは6
〜24時間である。架橋温度が100℃未満の場合は、
熱脱水架橋が十分にできないおそれがあり、170℃を
超える場合は、コラーゲンあるいは生体分解性合成高分
子の熱分解や熱劣化を引き起こすおそれがある。また、
架橋に要する時間が、2時間未満の場合は、温度にも依
存するが、熱脱水架橋が十分にできないおそれがあり、
120時間を越える場合は、コラーゲンあるいは生体分
解性合成高分子の熱分解や熱劣化を引き起こすおそれが
ある。When chemical cross-linking is performed, a cross-linking agent such as glutaraldehyde, carbodiimide, carbonylimidazole, diepoxy compound, diacid anhydride and epichlorohydrin may be used, and a known cross-linking method may be used. When thermally dehydrating and crosslinking under vacuum, there is no particular limitation, but specifically, the crosslinking temperature is preferably 100 to 170 ° C, more preferably 110 to 160 ° C.
It is more preferably 120 to 160 ° C., and the time required for crosslinking is preferably 2 to 120 hours, more preferably 3 to 100 hours, and even more preferably 6
~ 24 hours. If the cross-linking temperature is less than 100 ° C,
There is a possibility that thermal dehydration cross-linking cannot be sufficiently performed, and if the temperature exceeds 170 ° C., there is a risk of causing thermal decomposition or thermal deterioration of collagen or biodegradable synthetic polymer. Also,
If the time required for crosslinking is less than 2 hours, it may depend on the temperature, but there is a possibility that thermal dehydration crosslinking cannot be sufficiently performed.
If it exceeds 120 hours, the collagen or biodegradable synthetic polymer may be thermally decomposed or deteriorated.
【0020】紫外線照射による場合は、特に限定はされ
ないが、具体的には、紫外線の波長は、200〜400
nmの紫外線を照射することが好ましく、より好ましく
は200〜350nm、さらにより好ましくは200〜
300nm、特に好ましくは254nmであり、紫外線
の照射時間は、1分〜24時間であることが好ましく、
より好ましくは3分〜18時間、さらにより好ましくは
3分〜10時間である。紫外線の波長が、200nm未
満の場合は、コラーゲンあるいは生体分解性合成高分子
の分解や劣化を引き起こすおそれがあり、400nmを
越える場合は、十分に架橋できないおそれがある。ま
た、照射時間が、1分未満の場合は十分に架橋できない
おそれがあり、24時間を越える場合は、コラーゲンあ
るいは生体分解性合成高分子の分解や劣化を引き起こす
おそれがある。The irradiation with ultraviolet rays is not particularly limited, but specifically, the wavelength of ultraviolet rays is 200 to 400.
It is preferable to irradiate ultraviolet rays of nm, more preferably 200 to 350 nm, and even more preferably 200 to 350 nm.
300 nm, particularly preferably 254 nm, and the irradiation time of ultraviolet rays is preferably 1 minute to 24 hours,
It is more preferably 3 minutes to 18 hours, and even more preferably 3 minutes to 10 hours. When the wavelength of ultraviolet rays is less than 200 nm, collagen or biodegradable synthetic polymer may be decomposed or deteriorated, and when it exceeds 400 nm, sufficient crosslinking may not be possible. Further, if the irradiation time is less than 1 minute, sufficient crosslinking may not be possible, and if it exceeds 24 hours, collagen or biodegradable synthetic polymer may be decomposed or deteriorated.
【0021】このようにして得られる生体組織再生用の
複合材料は、架橋した天然高分子からなるミクロポーラ
スなスポンジの中に、繊維状の生体分解吸収性合成高分
子がランダムに埋入され存在してなる形態を有する。よ
って、細胞との親和性に優れ、組織再生に要する期間に
は十分な力学的強度が保持でき、しかも組織再生後には
速やかに分解消失させることができる適度な生体分解性
を兼ね備えたものとなる。従って、例えば、皮膚、歯
肉、歯髄、骨髄、筋肉および脂肪等の軟組織、神経組
織、軟骨組織、骨組織、肝臓、膵臓、精巣、卵巣および
腎臓等の内分泌組織、食道や胃腸等の消化管、気管、膀
胱、尿管および尿道等の泌尿器器官、歯、目の周辺組
織、血管、リンパ管、涙管などの管組織、唾液腺、汗
腺、脂腺などの腺組織、歯周組織、腱、じん帯等の欠損
部を再生させるための、細胞の増殖、分化を行う際の足
場材料として有用であるが、本発明の培養方法では、上
記複合材料は、骨髄幹細胞のin−vitroにおける
増殖、分化のための培養の足場材料として有効に利用さ
れる。The thus obtained composite material for regenerating biological tissue is a microporous sponge composed of a crosslinked natural polymer in which fibrous biodegradable and absorbable synthetic polymer is randomly embedded. It has the form Therefore, it has excellent affinity with cells, can maintain sufficient mechanical strength during the period required for tissue regeneration, and has appropriate biodegradability that can be rapidly decomposed and eliminated after tissue regeneration. . Therefore, for example, skin, gingiva, pulp, bone marrow, soft tissue such as muscle and fat, nerve tissue, cartilage tissue, bone tissue, liver, pancreas, testis, endocrine tissue such as ovary and kidney, digestive tract such as esophagus and gastrointestinal tract, Urinary organs such as the trachea, bladder, ureter and urethra, teeth, peripheral tissues of the eye, blood vessels, ductal tissues such as lymphatic vessels and lacrimal ducts, salivary glands, glandular tissues such as sweat glands and sebaceous glands, periodontal tissues, tendons, ligaments It is useful as a scaffold material for cell proliferation and differentiation for regenerating a defective portion such as, but in the culture method of the present invention, the composite material is used for proliferation and differentiation of bone marrow stem cells in vitro. It is effectively used as a scaffold material for culture.
【0022】本発明の培養方法における支持体として
は、上記複合材料のみではなく、他の材料を併用しても
よい。上記他の材料としては、特に限定はされないが、
具体的には、例えば、ハイドロキシアパタイト(hyd
roxyapatite(HAP))、tri−cal
cium phosphate(TPC)、Poly
(DL−lactic−co−glycolic ac
id(PLGA)多孔体、コラーゲンスポンジ(col
lagen sponge)などを挙げることができ
る。支持体全体中の、上記他の材料の含有割合は、上記
複合材料の効果を極端に妨げない程度で用いるのが好ま
しい。As the support in the culture method of the present invention, not only the above composite material but also other materials may be used in combination. The other material is not particularly limited,
Specifically, for example, hydroxyapatite (hyd
roxyapatite (HAP)), tri-cal
cium phosphate (TPC), Poly
(DL-lactic-co-glycolic ac
id (PLGA) porous material, collagen sponge (col
lagen sponge) and the like. The content ratio of the other material in the whole support is preferably such that the effect of the composite material is not extremely hindered.
【0023】本発明の骨髄幹細胞の培養方法において用
いる動物細胞培養液としては、特に限定されるわけでは
なく、例えば、通常一般的に、骨髄幹細胞や各種生体組
織細胞の培養に用いることのできる動物細胞培養用の培
養液であればよいが、血清およびホルモン物質を含む動
物細胞培養液であることが好ましい。上記動物細胞培養
液のベースメディウムとしては、天然培地であっても合
成培地であってもよく、特に限定はされないが、動物由
来物質からの細菌やウイルスなどの感染、供給の時期や
場所による組成のばらつき等の点を考慮すれば、合成培
地がより好ましい。合成培地としては、特に限定はされ
ないが、具体的には、例えば、α−MEM(ALPHA
−MINIMUM ESSENTIAL MEDIU
M)、Eagle MEM、Dulbeco MEM、
RPM±−1640、CMRC、HAM、DME/F1
2、199培地、MCDB培地、IMEMなどを挙げる
ことができる。天然培地としては、通常公知の天然培地
を挙げることができ、特に限定はされない。これらは単
独で用いても、2種以上を併用してもよい。The animal cell culture medium used in the method for culturing bone marrow stem cells of the present invention is not particularly limited, and, for example, animals that can be generally used for culturing bone marrow stem cells and various biological tissue cells are generally used. It may be a culture medium for cell culture, but is preferably an animal cell culture medium containing serum and hormone substances. The base medium of the animal cell culture medium may be a natural medium or a synthetic medium, and is not particularly limited, but infection by bacteria or viruses from animal-derived substances, composition depending on the time and place of supply. In consideration of the variation of the above, a synthetic medium is more preferable. The synthetic medium is not particularly limited, and specifically, for example, α-MEM (ALPHA).
-MINIMUM ESSENTIAL MEDIU
M), Eagle MEM, Dulbeco MEM,
RPM ± -1640, CMRC, HAM, DME / F1
2, 199 medium, MCDB medium, IMEM and the like can be mentioned. As the natural medium, a generally known natural medium can be mentioned, and it is not particularly limited. These may be used alone or in combination of two or more.
【0024】動物細胞培養液に含まれる血清としては、
特に限定はされないが、具体的には、例えば、仔牛胎児
血清、ヒト自己血清、市販のヒト血清、ウマ血清などを
挙げることができる。これらは単独で用いても、2種以
上を併用してもよい。血清は、細胞増殖因子などを含み
細胞の増殖を促進させる、細胞接着因子などを含み細胞
の細胞基質(支持体)への接着を促進させる等の役割を
果たす成分であるため、上記動物細胞培養液の必須要素
とする。また、ウマ血清は細胞の選別に使用できる。ま
た、同様に、動物細胞培養液に含まれるホルモン物質と
しては、特に限定はされないが、具体的には、例えば、
インシュリン、トランスフェリン、デキサメタゾン、ヒ
ドロコルチゾン、チロキシン、3,3’,5−トリヨー
ドチロニン、β−メルカプトエタノール、ジメチルスル
ホキシド、1−メチル−3−ブチルキサンチン、プロゲ
ステロン、ブチル化ヒドロキシアニソールなどを挙げる
ことができる。これらは単独で用いても、2種以上を併
用してもよい。このうち、デキサメタゾンは、骨系細胞
への分化誘導に使用することができる。ホルモン物質
は、細胞の生存、分化誘導、分化状態維持等の役割を果
たす成分であるため、上記動物細胞培養液の必須要素と
する。The serum contained in the animal cell culture medium is
Specific examples thereof include, but are not limited to, fetal bovine serum, human autologous serum, commercially available human serum, and horse serum. These may be used alone or in combination of two or more. Serum is a component that contains cell growth factors and the like to promote the growth of cells, and contains cell adhesion factors and the like to play a role in promoting the adhesion of cells to cell substrates (supports). It is an essential element of liquid. Horse serum can also be used for cell selection. Similarly, the hormone substance contained in the animal cell culture medium is not particularly limited, but specifically, for example,
Insulin, transferrin, dexamethasone, hydrocortisone, thyroxine, 3,3 ′, 5-triiodothyronine, β-mercaptoethanol, dimethyl sulfoxide, 1-methyl-3-butylxanthine, progesterone, butylated hydroxyanisole and the like can be mentioned. it can. These may be used alone or in combination of two or more. Of these, dexamethasone can be used for inducing differentiation into bone cells. The hormonal substance is a component that plays a role of survival of cells, induction of differentiation, maintenance of differentiation state, and the like, and is therefore an essential element of the above-mentioned animal cell culture medium.
【0025】本発明の骨髄幹細胞の培養方法における動
物細胞培養液には、上記血清およびホルモン物質以外の
他の成分を添加してもよい。他の成分としては、特に限
定はされないが、具体的には、例えば、アスコルビン酸
(特に、L−アスコルビン酸)、β−グリセロホスフェ
ート、ビオチン、パントテン酸カルシウム、アスコルビ
ン酸二リン酸、ビタミンD3、亜セレン酸ナトリウム、
リノール酸、レチノイン酸、ピルビン酸、プトレッシ
ン、モノチオグリセロール、グルタミンなどを挙げるこ
とができる。これらは、単独で用いても、2種以上を併
用してもよい。該他の成分の、動物細胞培養液中の含有
量については、上記血清およびホルモン物質の効果を極
端に妨げない程度で用いるのが好ましい。The animal cell culture medium in the method for culturing bone marrow stem cells of the present invention may contain components other than the above-mentioned serum and hormonal substances. Other components are not particularly limited, and specifically, for example, ascorbic acid (particularly L-ascorbic acid), β-glycerophosphate, biotin, calcium pantothenate, ascorbic acid diphosphate, vitamin D 3 , Sodium selenite,
Examples thereof include linoleic acid, retinoic acid, pyruvic acid, putrescine, monothioglycerol and glutamine. These may be used alone or in combination of two or more. The content of the other components in the animal cell culture medium is preferably such that the effects of the serum and hormonal substances are not extremely disturbed.
【0026】本発明の培養方法は、骨髄幹細胞を増殖お
よび/または分化させる培養方法であるが、ここで、骨
髄幹細胞を分化させるとは、生体組織細胞まで最終分化
させることのみではなく、生体組織細胞に至るまでの分
化過程における各段階の分化状態の細胞、例えば、前駆
細胞や芽細胞等の中間細胞への分化も含むとする。ま
た、上記培養方法では、骨髄幹細胞そのものを増殖させ
ることも、骨髄細胞を分化させるとともに増殖させるこ
とも含むとし、さらに、最終的に生体組織とするために
形態形成させることも含んでいてよいとする。具体的に
は、例えば、骨髄幹細胞を所望の生体組織細胞にまで最
終分化させることだけではなく、その生体組織細胞を増
殖させることや、さらに形態形成させることも含んでい
てよい。The culturing method of the present invention is a culturing method for proliferating and / or differentiating bone marrow stem cells. Here, differentiating bone marrow stem cells means not only terminal differentiation into living tissue cells but also living tissue. Differentiation into cells in each stage of differentiation in the differentiation process up to cells, for example, intermediate cells such as progenitor cells and blast cells is also included. In addition, the above-mentioned culturing method may include proliferating bone marrow stem cells themselves, including proliferating together with differentiating bone marrow cells, and further may include morphogenesis to finally obtain a living tissue. To do. Specifically, for example, not only the terminal differentiation of bone marrow stem cells into desired biological tissue cells but also proliferation of the biological tissue cells and further morphogenesis may be included.
【0027】骨髄幹細胞としては、特に限定はされるわ
けではなく、骨髄間葉系幹細胞や造血幹細胞などを含む
が、具体的には、例えば、動物の骨髄組織から無菌的に
取り出した骨髄細胞;動物の歯髄組織から無菌的に取り
出した歯髄細胞;動物から無菌的に取り出した各種血球
細胞等を、コラーゲンゲル上で初代培養してコラーゲン
ゲルに付着した細胞を単離したものが好ましい。なお、
コラーゲンがない状態でも通常の培養ディッシュに付着
させ単離したものでもよい。より具体的には、無菌的に
取り出された細胞を、細胞の成育に悪影響を与える交雑
物を除くため(培養時のコンタミネーションを防ぐた
め)、上述の培養液で洗浄し、EGTA(エチレングリ
コールビス(2−アミノエチルエーテル)四酢酸)処理
をした後、遠心分離などの操作で回収して、上記初代培
養に供することにより得られたものが好ましい。また、
上記初代培養は、特に限定はされないが、具体的には、
例えば、5%CO2、37℃のインキュベーター内でコ
ラーゲンゲル上で行われることが好ましい。初代培養さ
れた細胞は、コラーゲンを消化する酵素(例えば、コラ
ゲナーゼ等)でコラーゲンゲルを消化することにより、
コラーゲンゲルに付着している状態から単離して得ら
れ、本発明の培養方法に用いられることが好ましい。The bone marrow stem cells are not particularly limited and include bone marrow mesenchymal stem cells and hematopoietic stem cells. Specifically, for example, bone marrow cells aseptically taken from animal bone marrow tissue; It is preferable that dental pulp cells aseptically taken out from the dental pulp tissue of an animal; various blood cells and the like aseptically taken out from an animal are subjected to primary culture on a collagen gel to isolate cells attached to the collagen gel. In addition,
Even without collagen, it may be attached to a normal culture dish and isolated. More specifically, aseptically removed cells are washed with the above-mentioned culture solution in order to remove hybrids that adversely affect cell growth (to prevent contamination during culture), and EGTA (ethylene glycol). After being treated with bis (2-aminoethyl ether) tetraacetic acid, the product obtained by recovering by an operation such as centrifugation and subjecting it to the above primary culture is preferable. Also,
The primary culture is not particularly limited, but specifically,
For example, it is preferably performed on a collagen gel in an incubator at 37 ° C. with 5% CO 2 . Primary cultured cells can be prepared by digesting a collagen gel with an enzyme that digests collagen (for example, collagenase).
It is preferably obtained by isolation from the state of being attached to collagen gel and used in the culture method of the present invention.
【0028】なお、本発明の培養方法においては、骨髄
幹細胞のみではなく、骨髄幹細胞から最終分化した生体
組織細胞や、該分化過程における前駆細胞や芽細胞など
の各種中間細胞等を用いて培養する(増殖させる、分化
させる)こともできる。これら骨髄幹細胞、生体組織細
胞、中間細胞は、必要に応じ、低温保存や凍結保存して
おいて用いることが好ましい。本発明の培養方法は、前
述した支持体上で、上記骨髄幹細胞を培養するが、支持
体上で培養するとは、具体的には、支持体の表面に上記
骨髄幹細胞を通常の手法により播種して培養する、いわ
ゆる二次元的培養であってもよいし、あるいは、支持体
中に通常の手法(例えば、支持体表面に細胞を播種した
後この細胞の上にさらに支持体材料を形成して覆う方法
や、支持体内に細胞懸濁液を注入する方法、支持体表面
に細胞懸濁液をのせて自然に細胞を支持体内に浸み込ま
せる方法、支持体を作製するための懸濁液に予め細胞も
懸濁させておく方法など)により包埋するような形態で
播種して培養する、いわゆる三次元的培養であってもよ
く、特に限定はされない。In the culturing method of the present invention, not only bone marrow stem cells but also living tissue cells terminally differentiated from bone marrow stem cells and various intermediate cells such as progenitor cells and blast cells in the differentiation process are used for culturing. It can also be (proliferated, differentiated). These bone marrow stem cells, biological tissue cells, and intermediate cells are preferably used after cryopreservation or cryopreservation as necessary. The culture method of the present invention comprises culturing the above-mentioned bone marrow stem cells on the above-mentioned support, and culturing on the support specifically means that the above-mentioned bone marrow stem cells are seeded on the surface of the support by a usual method. It may be a so-called two-dimensional culture, or it may be an ordinary method (for example, seeding cells on the surface of the support and then forming a support material on the cells). Method of covering, method of injecting cell suspension into the support, method of placing cell suspension on the surface of the support to allow cells to naturally permeate into the support, and suspension for preparing the support The method may be so-called three-dimensional culture, in which cells are seeded and cultured in such a manner that they are embedded by a method in which cells are also suspended in advance), and there is no particular limitation.
【0029】本発明の培養方法において、骨髄幹細胞を
増殖させるために培養する場合、および/または、骨髄
幹細胞を所望の生体組織細胞へ分化させる若しくは該分
化過程の各種中間細胞へ分化させる場合やこれら生体組
織細胞や中間細胞をさらに増殖させる場合は、例えば培
養液中の血清およびホルモン物質の種類や添加量などの
各種培養諸条件については、通常公知の条件等を適宜選
択して行えばよい。また、骨髄幹細胞から最終分化させ
て得られる生体組織細胞としては、特に限定されるわけ
ではなく、生体硬組織細胞や生体軟組織細胞など、どの
ような生体組織細胞を目的の細胞としてもよいが、具体
的には、例えば、骨芽細胞、破骨細胞、軟骨芽細胞、歯
根膜細胞、脂肪細胞、筋肉細胞、神経細胞等を挙げるこ
とができる。これら生体組織細胞は、1種のみであって
も、2種以上が共存しているものであってもよい。In the culturing method of the present invention, when culturing to proliferate bone marrow stem cells, and / or when differentiating bone marrow stem cells into desired living tissue cells or into various intermediate cells in the differentiation process, In the case of further proliferating living tissue cells and intermediate cells, various culture conditions such as the type and addition amount of serum and hormone substances in the culture medium may be appropriately selected from commonly known conditions. The biological tissue cells obtained by terminally differentiating from bone marrow stem cells are not particularly limited, and any biological tissue cells such as biological hard tissue cells and biological soft tissue cells may be the target cells, Specific examples include osteoblasts, osteoclasts, chondroblasts, periodontal ligament cells, adipocytes, muscle cells, nerve cells, and the like. These living tissue cells may be only one type or two or more types may coexist.
【0030】本発明にかかる生体組織様構造体(以下、
本発明の生体組織様構造体と称することがある。)は、
架橋した天然高分子からなるスポンジ中に生体分解性合
成高分子が繊維状の形態で存在してなる複合材料を必須
材料として構成された支持体に、動物細胞培養液が含ま
れ、かつ、骨髄細胞、および/または、骨髄幹細胞から
分化した生体組織細胞、および/または、骨髄細胞から
生体組織細胞への分化過程における中間細胞が支持され
てなる、生体組織様構造体である。本発明の生体組織様
構造体は、例えば、生体組織や臓器の欠損部への再生用
の移植用材料として用いられたり、in−vitroで
の細胞の薬理学、組織学、生理学的および病理学的検査
を行うために用いられたりすることが好ましいが、特に
用途は限定されない。The biological tissue-like structure according to the present invention (hereinafter,
It may be referred to as the biological tissue-like structure of the present invention. ) Is
A support composed of a composite material consisting of a biodegradable synthetic polymer present in a fibrous form in a sponge composed of a crosslinked natural polymer as an essential material contains an animal cell culture solution, and contains bone marrow. A biological tissue-like structure in which cells and / or biological tissue cells differentiated from bone marrow stem cells and / or intermediate cells in the process of differentiation from bone marrow cells to biological tissue cells are supported. The biological tissue-like structure of the present invention is used, for example, as a transplant material for regeneration of a defective portion of a biological tissue or an organ, or in-cell pharmacology, histology, physiological and pathology of cells. Although it is preferably used for conducting a physical examination, its use is not particularly limited.
【0031】本発明の生体組織様構造体は、上記本発明
の培養方法により得られるものであることが好ましい。
また、本発明の生体組織様構造体において、支持体、骨
髄幹細胞、分化した生体組織細胞、分化過程における中
幹細胞および動物細胞培養液等については、上記本発明
の培養方法の説明で記載したものと同様であることが好
ましい。具体的には、上記生体組織細胞とは、骨髄幹細
胞から最終分化した生体組織細胞であり、上記中間細胞
とは、骨髄幹細胞から上記生体組織細胞への分化過程に
おける各段階の分化状態の細胞、例えば、前駆細胞や芽
細胞などである。また、本発明の生体組織様構造体にお
いては、支持体に生体組織細胞が支持されてなる場合
は、最終的に生体組織として形態形成させた状態も含ん
でいてよいとする。The biological tissue-like structure of the present invention is preferably obtained by the above-mentioned culture method of the present invention.
Further, in the biological tissue-like structure of the present invention, the support, bone marrow stem cells, differentiated biological tissue cells, medium stem cells in the differentiation process, animal cell culture medium, etc. are those described in the description of the culturing method of the present invention. It is preferably the same as Specifically, the biological tissue cells are biological tissue cells that have been terminally differentiated from bone marrow stem cells, and the intermediate cells, cells in the differentiated state of each stage in the differentiation process from bone marrow stem cells to the biological tissue cells, For example, progenitor cells and blast cells. Further, in the biological tissue-like structure of the present invention, when the biological tissue cells are supported by the support, it may include a state in which the biological tissue is finally morphologically formed.
【0032】本発明の生体組織様構造体においては、支
持体に、骨髄幹細胞や上記生体組織細胞や上記中間細胞
が支持されており、該生体組織細胞や中間細胞としては
目的とする移植部分に好適な生体組織細胞または中間細
胞として分化させているものや、前述したような各種検
査の対象とする生体組織細胞や中間細胞として分化させ
ているものが好ましいが、骨髄幹細胞やこれら生体組織
細胞または中間細胞に限らず、別の組織や臓器に用い得
る生体組織細胞などの他の細胞も共に支持されていても
よいとする。また、支持体に支持されている形態として
は、特に限定はされないが、具体的には、支持体の表面
上に接着し二次元的に支持されている形態であっても、
スポンジ状構造を有する支持体の内部の任意の各所に接
着し3次元的に支持されている形態であってもよく、さ
らに、これら両形態を合わせた形態であってもよいとす
るが、本発明の生体組織様構造体を移植に用いる上で
は、スポンジ状構造を有する支持体の内部に3次元的に
支持されている形態が好ましい。また、2種類以上の細
胞が入っている場合には、それらの細胞が別々に存在し
ていても、混合されていてもよく、層状、海島状などあ
る規則性をもって細胞あるいは細胞集合体が分布してい
てもよい。上記各種検査に用いる生体組織様構造物の場
合には、あらゆる種類の細胞の組み合わせが考えられ
る。In the biological tissue-like structure of the present invention, bone marrow stem cells, the biological tissue cells or the intermediate cells are supported by the support, and the biological tissue cells or the intermediate cells are used as the target transplanted portion. Those differentiated as suitable living tissue cells or intermediate cells, and those differentiated as living tissue cells or intermediate cells to be subjected to various tests as described above are preferable, but bone marrow stem cells or these living tissue cells or Not only the intermediate cells but also other cells such as living tissue cells that can be used for another tissue or organ may be supported together. The form supported by the support is not particularly limited, but specifically, even in the form of being two-dimensionally supported by being adhered onto the surface of the support,
The sponge-like support may be in a form of being three-dimensionally supported by adhering to various places inside the support, and may be a combination of both forms. When the biological tissue-like structure of the present invention is used for transplantation, it is preferable that it is three-dimensionally supported inside a support having a sponge-like structure. When two or more types of cells are contained, the cells may be present separately or mixed, and the cells or cell aggregates are distributed with a certain regularity such as a layered or sea-island shape. You may have. In the case of the biological tissue-like structure used for the above various tests, combinations of all kinds of cells are possible.
【0033】本発明の生体組織様構造体は、移植用材料
として用いる場合は、歯周病治療、歯周組織再生療法、
歯周病により吸収された歯槽骨や歯根膜の再生におい
て、骨欠損部の修復材、歯根膜細胞複合化インプラント
材などのハイブリッド型の修復材として、骨折や先天的
な骨の欠陥および外科的に生じた骨の欠損等の骨欠損部
や、補遺を必要とする骨の構造および歯周の欠陥(例え
ば、歯根膜細胞の欠損)等の、生体の硬組織の欠損部な
どに対して、整形外科や歯科などの医師によく知られた
標準的な外科的手術(例えば、骨髄または骨片だけを供
給する際に用いられる方法)を用いて移植され得る。ま
た、筋肉、皮膚、脂肪等の他の生体の軟組織における欠
損部などに対して、脳神経外科、形成外科、眼科、耳鼻
咽喉科、皮膚科、小児科、一般外科、心臓血管科、胸部
外科、腹部科、整形外科などの医師によく知られた標準
的な外科的手術(例えば、皮膚だけを供給する際に用い
られる方法)を用いて移植され得る。移植に先立って、
組織適合性をチェックする必要があることおよびその方
法も、従来の移植用材料に対する扱いと同様である。When the living tissue-like structure of the present invention is used as a material for transplantation, it is used for periodontal disease treatment, periodontal tissue regeneration therapy,
In the regeneration of alveolar bone and periodontal ligament absorbed by periodontal disease, as a hybrid type repairing material such as a bone defect repair material, periodontal ligament cell composite implant material, fractures and congenital bone defects and surgical For bone defects such as bone defects that have occurred in the body, defects of bone structure and periodontal defects (such as periodontal ligament cell defects) that require supplements, etc. It can be implanted using standard surgical procedures well known to physicians such as orthopedics and dentistry (eg, the method used to supply only bone marrow or bone fragments). In addition, for defects such as muscle, skin, and soft tissue of other organisms such as fat, neurosurgery, plastic surgery, ophthalmology, otolaryngology, dermatology, pediatrics, general surgery, cardiovascular department, thoracic surgery, abdomen It can be implanted using standard surgical procedures well known to physicians such as departments, orthopedics, such as those used in supplying skin alone. Prior to transplantation
The need and method of checking for tissue compatibility is similar to that of traditional implantable materials.
【0034】前述のように、本発明の生体組織様構造体
においては、所望の動物細胞培養液を含んだ状態で生体
に移植されたり各種検査に用いられたりするが、具体的
には、上記生体組織細胞が支持されている支持体が該培
養液を(スポンジが水分を含むように)含浸してなる形
態であってもよいし、該培養液に上記生体組織細胞が支
持されている支持体が浸されている形態(さらには浸さ
れた状態で包装されている形態)であっても、これらを
合わせた形態であってもよく、特に限定はされない。本
発明にかかる培養用キット(以下、本発明の培養用キッ
トと称することがある。)は、架橋した天然高分子から
なるスポンジ中に生体分解性合成高分子が繊維状の形態
で存在してなる複合材料を必須材料として構成された支
持体、骨髄幹細胞、および/または、骨髄幹細胞から分
化した生体組織細胞、および/または、前記分化過程に
おける中間細胞、ならびに、動物細胞培養液をそれぞれ
独立に構成要素として含む培養用キットであり、また、
これら構成要素の中の少なくとも1つを含む培養用キッ
トであってもよいが、いずれにおいてもこれら構成要素
以外に他の構成要素を含んでいてもよい。As described above, the living tissue-like structure of the present invention may be transplanted to a living body in a state containing a desired animal cell culture solution or used for various tests. The support on which the biological tissue cells are supported may be in the form of being impregnated with the culture fluid (so that the sponge contains water), or the support on which the biological tissue cells are supported in the culture fluid. The body may be dipped (further, it may be packaged in a dipped state), or may be a combination thereof, and is not particularly limited. The culture kit according to the present invention (hereinafter, also referred to as the culture kit of the present invention) has a biodegradable synthetic polymer present in a fibrous form in a sponge composed of a crosslinked natural polymer. The support, the bone marrow stem cells, and / or the living tissue cells differentiated from the bone marrow stem cells, and / or the intermediate cells in the differentiation process, and the animal cell culture medium, which are composed of the composite material A culture kit including as a component,
The culture kit may include at least one of these components, but any of the components may include other components in addition to these components.
【0035】本発明の培養用キットは、例えば、上記本
発明の培養方法を行うために用いることができる。ま
た、本発明の培養用キットにおいて、支持体、骨髄幹細
胞、分化した生体組織細胞、分化過程における中幹細胞
および動物細胞培養液等については、上記本発明の培養
方法の説明で記載したものと同様であることが好まし
い。具体的には、上記生体組織細胞とは、骨髄幹細胞か
ら最終分化した生体組織細胞であり、上記中間細胞と
は、骨髄幹細胞から上記生体組織細胞への分化過程にお
ける各段階の分化状態の細胞、例えば、前駆細胞や芽細
胞などである。本発明の培養用キットには、上述のよう
に骨髄幹細胞や上記生体組織細胞や上記中間細胞を含む
が、これら細胞は、本キットの構成要素として、例え
ば、通常、細胞の生活性を維持できる程度の条件化で保
存された状態であって、本発明のキットを用いて培養を
行う際に、細胞の増殖や分化または生体組織形態形成を
行うことができる状態であればよい。また、上記生体組
織細胞や中間細胞を含む場合は、予め所望の条件下で骨
髄幹細胞から分化および/または増殖させたものを用い
ればよいとする。The culture kit of the present invention can be used, for example, to carry out the culture method of the present invention. Further, in the culture kit of the present invention, the support, bone marrow stem cells, differentiated biological tissue cells, medium stem cells in the differentiation process, animal cell culture medium and the like are the same as those described in the explanation of the culture method of the present invention. Is preferred. Specifically, the biological tissue cells are biological tissue cells that have been terminally differentiated from bone marrow stem cells, and the intermediate cells, cells in the differentiated state of each stage in the differentiation process from bone marrow stem cells to the biological tissue cells, For example, progenitor cells and blast cells. The culture kit of the present invention contains the bone marrow stem cells, the biological tissue cells, and the intermediate cells as described above, and these cells are, for example, the components of the kit, and can usually maintain the cell viability. It may be stored in a condition of a certain degree, and can be in a state capable of proliferating and differentiating cells or forming morphology of living tissue when culturing using the kit of the present invention. Further, when the above-mentioned living tissue cells or intermediate cells are contained, those differentiated and / or expanded from bone marrow stem cells under desired conditions may be used.
【0036】本発明の培養用キットにおいて、動物細胞
培養液は、既に必要な成分や所望の成分が添加され培養
液として調製されている状態であってもよいし、各成分
が別々の状態で備えられていてもよく、また、本発明の
キットを用いて培養を行う際に、使用者の方で培養液を
調製できるよう例えば必要成分等を粉末などの状態にし
て備えられていてもよく、最終的に上記動物細胞培養液
を調製できる状態で備えられていれば、特に限定はされ
ない。本発明の培養用キットにおいては、支持体につい
ても同様に適宜所望の状態で備えておくことができる。
具体的には、例えば、支持体そのものをそのままの状態
で備えていても、何らかの保存液に浸漬させて備えてお
いてもよいとする。In the culture kit of the present invention, the animal cell culture medium may be in a state of being prepared as a culture medium by adding necessary or desired components, or each component may be in a separate state. It may be provided, or when carrying out culture using the kit of the present invention, for example, necessary components and the like may be provided in a powder state so that the user can prepare a culture solution. There is no particular limitation as long as the animal cell culture solution can be prepared finally. In the culture kit of the present invention, the support can be similarly provided in a desired state.
Specifically, for example, the support itself may be provided as it is, or may be provided by immersing it in some kind of storage solution.
【0037】上記他の構成要素としては、特に限定はさ
れないが、具体的には、例えば、培養容器などの通常足
場材料となる支持体を用いて骨髄幹細胞等を培養する場
合に用いる物品等や、抗生物質等の種々の添加剤を挙げ
ることができる。これらは、1種のみ含んでいても2種
以上含んでいてもよい。The above-mentioned other components are not particularly limited, but specifically, for example, articles used when culturing bone marrow stem cells and the like using a support which is usually a scaffold material such as a culture container, , Various additives such as antibiotics. These may contain only 1 type and may contain 2 or more types.
【0038】[0038]
【実施例】以下に、実施例により、本発明をさらに具体
的に説明するが、本発明はこれらにより何ら限定される
ものではない。なお、以下では、便宜上、「重量部」を
単に「部」と記すことがある。また、「重量%」を単に
「wt%」と記すことがある。
−実施例1−
〔PGA−コラーゲンスポンジの調製〕ポリグリコール
酸(PGA)からなる不織布3mg分を切り出し、ピン
セットで均一にほぐし、シリコン(「シグマコート」S
IGMA社製)でコーティングしたアルミキャップ(2
0mmφ、34mmH)の中に入れた。次に、0.3重
量%の豚皮由来I型コラーゲン溶液1.5gに、クロロ
ホルムをクロロホルム濃度が約5重量%となるように添
加し、ジェネレーターシャフト付ホモジナイザーを用い
て12000rpmで3分間攪拌した後、該溶液を前記
アルミキャップに添加した。次いで、該アルミキャップ
を−80℃で12時間凍結した後、0.1トール未満の
真空下で24時間凍結乾燥を行った。その後、140
℃、0.1トール未満の真空下で12時間熱脱水架橋を
行い、ポリグリコール酸/コラーゲン=0.67(重量
比)であるPGA−コラーゲンスポンジ複合材料を得
た。
〔骨髄間葉系幹細胞の調製〕フィッシャー系ラット(F
344、雄、7週齢)をエーテル麻酔下で屠殺後、左右
の大腿骨を採取した。採取した大腿骨を氷上の滅菌済み
のシャーレに静置、骨幹部の筋組織を除去した後、大腿
骨の両端を切除した。注射筒(1.8G、2.5ml)
に10%牛胎児血清含有α−MEM(GIBCO社製)
を1ml入れ、大腿骨両端から0.5mlずつ注入して
骨髄を採取した。得られた骨髄を50mlチューブに集
めた後、直径10.0cmのディッシュを用い、10%
牛胎児α−MEM(ペニシリン100unit/ml、
ストレプトマイシン0.1g/ml)中で、37℃、5
%CO2の条件下にて培養した。3日後に、浮遊細胞を
除去し、ディッシュ表面に付着した接着細胞を骨髄間葉
系幹細胞として回収した。回収した細胞をsubcon
fluent(増殖細胞がディッシュ表面の80%程度
をカバーする状態)になるまで培養した後、2日間継代
培養して、骨髄間葉系幹細胞を調製した。
〔三次元培養〕調製した骨髄間葉系幹細胞をトリプシン
処理し、α−MEM細胞浮遊液とした。直径1.8c
m、高さ3mmのPGA−コラーゲンスポンジを培養支
持体とし、これに調製した骨髄間葉系幹細胞を注射針
(21G)を用いて5×106cells/スポンジと
なるように播種し、b−FGF(2.5ng/ml、科
研製薬社製)およびデキサメタゾン(10nM、和光純
薬社製)を含有した10%牛胎児血清含有α−MEM
(GIBCO社製)培養液中で、21日間培養した。EXAMPLES The present invention will be described in more detail below with reference to examples, but the present invention is not limited thereto. In the following, "parts by weight" may be simply referred to as "parts" for convenience. In addition, "wt%" may be simply referred to as "wt%". -Example 1- [Preparation of PGA-collagen sponge] 3 mg of a non-woven fabric made of polyglycolic acid (PGA) was cut out and uniformly loosened with tweezers, and then silicon ("Sigma Coat" S
Aluminum cap coated with IGMA (2)
0 mmφ, 34 mmH). Next, chloroform was added to 1.5 g of a pig skin-derived type I collagen solution of 0.3% by weight so that the chloroform concentration was about 5% by weight, and the mixture was stirred at 12000 rpm for 3 minutes using a homogenizer with a generator shaft. Then, the solution was added to the aluminum cap. Then, the aluminum cap was frozen at −80 ° C. for 12 hours, and then freeze-dried for 24 hours under a vacuum of less than 0.1 Torr. Then 140
Thermal dehydration cross-linking was performed for 12 hours under vacuum at a temperature of less than 0.1 Torr to obtain a PGA-collagen sponge composite material having polyglycolic acid / collagen = 0.67 (weight ratio). [Preparation of bone marrow mesenchymal stem cells] Fischer rat (F
(344, male, 7 weeks old) were sacrificed under ether anesthesia, and the left and right femurs were collected. The collected femur was left to stand on a sterilized petri dish on ice to remove the muscle tissue of the diaphysis, and both ends of the femur were excised. Syringe (1.8G, 2.5ml)
Α-MEM containing 10% fetal bovine serum (manufactured by GIBCO)
1 ml was put and 0.5 ml was injected from both ends of the femur to collect bone marrow. After collecting the obtained bone marrow in a 50 ml tube, use a dish with a diameter of 10.0 cm to obtain 10%.
Fetal bovine α-MEM (penicillin 100 unit / ml,
Streptomycin 0.1 g / ml) at 37 ° C. for 5
Culture was performed under the condition of% CO 2 . Three days later, the floating cells were removed, and the adherent cells attached to the dish surface were collected as bone marrow mesenchymal stem cells. Recovered cells from subcon
Bone marrow mesenchymal stem cells were prepared by culturing until fluent (a state in which proliferating cells cover about 80% of the dish surface) was subcultured for 2 days. [Three-dimensional culture] The prepared bone marrow mesenchymal stem cells were trypsinized to obtain an α-MEM cell suspension. Diameter 1.8c
m, 3 mm in height of PGA-collagen sponge was used as a culture support, and the bone marrow mesenchymal stem cells prepared therein were seeded using an injection needle (21G) at 5 × 10 6 cells / sponge, and b- Α-MEM containing 10% fetal bovine serum containing FGF (2.5 ng / ml, manufactured by Kaken Pharmaceutical Co., Ltd.) and dexamethasone (10 nM, manufactured by Wako Pure Chemical Industries, Ltd.).
It was cultured for 21 days in a culture medium (manufactured by GIBCO).
【0039】培養期間中、PGA−コラーゲンスポンジ
を、肉眼的および組織学的に観察し、該スポンジに支持
されてなる細胞のアルカリホスファターゼ活性の測定を
行った。該観察および測定については、後で詳述する。
−比較例1−
〔コラーゲンスポンジの調製〕0.3重量%の豚皮由来
I型コラーゲン溶液1.5gに、クロロホルムをクロロ
ホルム濃度が約5重量%となるように添加し、ジェネレ
ーターシャフト付ホモジナイザーを用いて12000r
pmで3分間攪拌した後、該溶液を、シリコン(「シグ
マコート」SIGMA社製)でコーティングしたアルミ
キャップ(20mmφ、34mmH)に添加した。次い
で、該アルミキャップを−80℃で12時間凍結した
後、0.1トール未満の真空下で24時間凍結乾燥を行
った。その後、140℃、0.1トール未満の真空下で
12時間熱脱水架橋を行い、比較用のコラーゲン単独材
料を得た。
〔三次元培養〕実施例1で調製した骨髄間葉系幹細胞を
トリプシン処理し、α−MEM細胞浮遊液とした。直径
1.8cm、高さ3mmのコラーゲンスポンジを培養支
持体とし、これに調製した骨髄間葉系幹細胞を注射針
(21G)を用いて5×106cells/スポンジと
なるように播種し、b−FGF(2.5ng/ml、科
研製薬社製)およびデキサメタゾン(10nM、和光純
薬社製)を含有した10%牛胎児血清含有α−MEM
(GIBCO社製)培養液中で、21日間培養した。During the culture period, the PGA-collagen sponge was visually and histologically observed to measure the alkaline phosphatase activity of the cells supported by the sponge. The observation and measurement will be described in detail later. -Comparative Example 1- [Preparation of Collagen Sponge] To 1.5 g of a 0.3% by weight pig skin-derived type I collagen solution, chloroform was added so that the chloroform concentration was about 5% by weight, and a homogenizer with a generator shaft was added. Using 12000r
After stirring at pm for 3 minutes, the solution was added to an aluminum cap (20 mmφ, 34 mmH) coated with silicon ("Sigma Coat" SIGMA). Then, the aluminum cap was frozen at −80 ° C. for 12 hours, and then freeze-dried for 24 hours under a vacuum of less than 0.1 Torr. Then, thermal dehydration crosslinking was performed for 12 hours at 140 ° C. under a vacuum of less than 0.1 Torr to obtain a collagen-only material for comparison. [Three-dimensional culture] The bone marrow mesenchymal stem cells prepared in Example 1 were trypsinized to obtain an α-MEM cell suspension. A collagen sponge having a diameter of 1.8 cm and a height of 3 mm was used as a culture support, and the prepared bone marrow mesenchymal stem cells were seeded using an injection needle (21G) at 5 × 10 6 cells / sponge, and b Α-MEM containing 10% fetal bovine serum containing FGF (2.5 ng / ml, manufactured by Kaken Pharmaceutical Co., Ltd.) and dexamethasone (10 nM, manufactured by Wako Pure Chemical Industries, Ltd.)
It was cultured for 21 days in a culture medium (manufactured by GIBCO).
【0040】実施例1と同様に、培養期間中、PGA−
コラーゲンスポンジを、肉眼的および組織学的に観察
し、該スポンジに支持されてなる細胞のアルカリホスフ
ァターゼ活性を行った。
≪肉眼的観察および組織学的観察≫
〔観察方法〕肉眼的観察としては、裸眼で観察すればよ
く、必要に応じてルーペ等の拡大鏡等を用い、これによ
って細胞の足場材料となる支持体の形状変化等を確認す
ることができる。As in Example 1, during the culture period, PGA-
The collagen sponge was observed macroscopically and histologically, and the alkaline phosphatase activity of the cells supported by the sponge was measured. <Macroscopic and histological observations> [Observation method] As the macroscopic observation, it may be observed with the naked eye, and if necessary, a magnifying glass such as a magnifying glass is used. It is possible to confirm the shape change and the like.
【0041】また、組織学的観察の方法は、培養後のス
ポンジを12well(容器)へ移し、PBS(−)で
10分間、3回洗浄した後、4%パラホルムアルデヒド
(in 0.1M PB)で固定した。通法に従い、薄
切片を作成し、ヘマトキシリンエオジン染色を行った。
これによって、細胞を染色することができ、細胞の形態
と細胞の局在を確認することができる。
〔観察結果・考察〕肉眼的観察では、比較例1で用いた
コラーゲンスポンジは、培養1日目から収縮が始まり、
培養9日目ではその直径が初めの1/3になっていた
が、実施例1で用いたPGA−コラーゲンゲルスポンジ
は、培養21日目においても初めの形態を保っていた。The method of histological observation was as follows. The sponge after culture was transferred to a 12-well (container), washed with PBS (-) for 10 minutes three times, and then 4% paraformaldehyde (in 0.1M PB). Fixed in. Thin sections were prepared and stained with hematoxylin and eosin according to a conventional method.
As a result, the cells can be stained, and the cell morphology and cell localization can be confirmed. [Observation Results / Discussion] In the macroscopic observation, the collagen sponge used in Comparative Example 1 begins to contract from the first day of culture,
The diameter of the PGA-collagen gel sponge used in Example 1 was maintained at the initial morphology on the 21st day of culture, although the diameter was 1/3 of that on the 9th day of culture.
【0042】組織学的観察では、比較例1では、培養後
ほとんどの細胞がスポンジ表面に見られたが、実施例1
では、スポンジ表面のみではなく、スポンジ内部にも多
く見られた。よって、PGA−コラーゲンスポンジは、
コラーゲンスポンジよりも三次元培養の足場材料として
有用なものであることが分かった。コラーゲンスポンジ
は、培養中、収縮したり変形したりするため、細胞がス
ポンジ内でも増殖しにくいのに対し、PGA−コラーゲ
ンスポンジでは、そのような収縮や変形がほとんどな
く、培養期間中、スポンジ内への細胞の進入増殖のため
の足場が最適に確保されるからである。
≪アルカリホスファターゼ活性測定≫
〔測定方法〕培養後のスポンジを12well(容器)
へ移し、PBS(−)で10分間、3回洗浄した。その
後、−30℃で24時間凍結保存を行った。測定時、凍
結、融解を繰り返した後、16mMのp−NPP(SI
GMA社製)を各wellに加えて、室温において20
分間振とうした。1NのNaOHを各wellに加えて
反応を停止し、MICRO PLATE READER
(TOSOH社製)を用いて、415〜600nmで測
定した。これによって、溶液の吸光度を測定でき、予め
作成しておいた吸光度とアルカリホスファターゼ活性と
の検量線から活性を求めることができる。
〔測定結果・考察〕実施例1におけるアルカリホスファ
ターゼ活性測定値は、比較例1のそれと比較すると明ら
かに高い値を示した。具体的には、実施例1の方が2.
3倍高い値を示した。Histological observation revealed that in Comparative Example 1, most cells were found on the sponge surface after culturing.
Then, not only on the surface of the sponge but also inside the sponge. Therefore, PGA-collagen sponge
It was found that it is more useful as a scaffold material for three-dimensional culture than collagen sponge. Since collagen sponge contracts and deforms during culture, cells do not proliferate even in the sponge, whereas PGA-collagen sponge hardly causes such contraction or deformation, and the sponge remains in the sponge during the culture period. This is because the scaffold for invading and proliferating cells into the cell is optimally secured. << Measurement of alkaline phosphatase activity >> [Measurement method] 12 wells (container) of sponge after culturing
And washed 3 times with PBS (-) for 10 minutes. Then, it was cryopreserved at -30 ° C for 24 hours. During the measurement, after repeated freezing and thawing, 16 mM p-NPP (SI
GMA) was added to each well and added at room temperature for 20
Shake for a minute. 1N NaOH was added to each well to stop the reaction, and MICRO PLATE READER
(Manufactured by Tosoh) was used to measure at 415 to 600 nm. With this, the absorbance of the solution can be measured, and the activity can be determined from the calibration curve of the absorbance and the alkaline phosphatase activity which has been prepared in advance. [Measurement Result / Discussion] The alkaline phosphatase activity measurement value in Example 1 was clearly higher than that in Comparative Example 1. Specifically, the first embodiment is 2.
The value was three times higher.
【0043】このようにPGA−コラーゲンスポンジを
用いた場合の活性が高かったのは、上述と同様に、培養
期間中のスポンジの収縮、変形がほとんど無かったため
である。骨髄幹細胞の培養方法においては、PGA−コ
ラーゲンスポンジは、in−vivoであってもex−
vivoであっても取り扱いまで含めて優れた特性を有
しており、生体組織再生等の移植用材料のscaffo
ld(足場、支持体)として非常に有用である。The reason why the activity was high when the PGA-collagen sponge was used was that there was almost no contraction or deformation of the sponge during the culture period as described above. In the method for culturing bone marrow stem cells, the PGA-collagen sponge is ex-
Even in vivo, it has excellent properties including handling, and is a scaffo for transplantation materials such as biological tissue regeneration.
Very useful as an ld (scaffold, support).
【0044】[0044]
【発明の効果】本発明によれば、培養中の足場の収縮が
なく、細胞に対する酸素や栄養物の供給にも優れるた
め、より効率の良い細胞の増殖、分化が期待され、ま
た、最終的に得られる細胞と足場材料との複合体も縮む
ことがないため、初期の設計どおりの移植用材料が得ら
れる等の優れた効果を得ることのできる骨髄幹細胞の培
養方法、この培養方法に用いることのできる培養用キッ
ト、および、生体組織様構造体を提供することができ
る。INDUSTRIAL APPLICABILITY According to the present invention, there is no contraction of scaffolds during culturing and excellent supply of oxygen and nutrients to cells, so that more efficient cell growth and differentiation are expected, and the final Since the complex of the cells and the scaffold material obtained in 1. does not shrink, a method for culturing bone marrow stem cells that can obtain excellent effects such as obtaining a transplant material as originally designed, and used for this culturing method It is possible to provide a culture kit and a biological tissue-like structure that can be obtained.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 田畑 泰彦 京都府宇治市琵琶台3−8−16 (72)発明者 木下 靭彦 神奈川県逗子市小坪1−21−17 (72)発明者 平岡 陽介 大阪府八尾市二俣2丁目22番地 新田ゼラ チン株式会社大阪工場内 Fターム(参考) 4B033 NA16 NB02 NB13 NB34 NB58 NB65 NB69 NC06 ND12 NG05 NH04 4B065 AA91X BC42 BD39 BD40 CA44 4C081 AA12 AA13 AA14 AB04 AB05 AB06 AB11 AB12 AB13 AB15 AB16 AB18 AB35 BA12 BA13 BA16 BB04 BB08 CA161 CA171 CA191 CC01 CC05 CD011 CD031 CD041 CD081 CD091 CD111 CD121 CD151 CD171 CD26 CD27 CD34 DA02 DA04 DA05 DA06 DB01 DC13 DC14 ─────────────────────────────────────────────────── ─── Continued front page (72) Inventor Yasuhiko Tabata 3-8-16 Biwadai, Uji City, Kyoto Prefecture (72) Inventor Takehiko Kinoshita 1-21-17 Kotsubo, Zushi City, Kanagawa Prefecture (72) Inventor Yosuke Hiraoka 2-22, Futamatata, Yao-shi, Osaka Nitta Zera Chin Co., Ltd. Osaka factory F-term (reference) 4B033 NA16 NB02 NB13 NB34 NB58 NB65 NB69 NC06 ND12 NG05 NH04 4B065 AA91X BC42 BD39 BD40 CA44 4C081 AA12 AA13 AA14 AB04 AB05 AB06 AB11 AB12 AB13 AB15 AB16 AB18 AB35 BA12 BA13 BA16 BB04 BB08 CA161 CA171 CA191 CC01 CC05 CD011 CD031 CD041 CD081 CD091 CD111 CD121 CD151 CD171 CD26 CD27 CD34 DA02 DA04 DA05 DA06 DB01 DC13 DC14
Claims (3)
生体分解性合成高分子が繊維状の形態で存在してなる複
合材料を必須材料として構成された支持体に、動物細胞
培養液が含まれ、かつ、骨髄幹細胞、および/または、
骨髄幹細胞から分化した生体組織細胞、および/また
は、前記分化過程における中間細胞が支持されてなる、
生体組織様構造体。1. A support composed essentially of a composite material comprising a biodegradable synthetic polymer present in a fibrous form in a sponge composed of a cross-linked natural polymer, containing an animal cell culture solution. And / or bone marrow stem cells and / or
Living tissue cells differentiated from bone marrow stem cells, and / or supporting intermediate cells in the differentiation process,
Biological tissue-like structure.
生体分解性合成高分子が繊維状の形態で存在してなる複
合材料を必須材料として構成された支持体と動物細胞培
養液とを用い、前記支持体上で骨髄幹細胞を増殖および
/または分化させる、骨髄幹細胞の培養方法。2. A support and an animal cell culture solution, which are composed of a composite material in which a biodegradable synthetic polymer is present in a fibrous form in a sponge composed of a crosslinked natural polymer as an essential material. A method for culturing bone marrow stem cells, which comprises proliferating and / or differentiating bone marrow stem cells on the support.
生体分解性合成高分子が繊維状の形態で存在してなる複
合材料を必須材料として構成された支持体、骨髄幹細
胞、および/または、骨髄幹細胞から分化した生体組織
細胞、および/または、前記分化過程における中間細
胞、ならびに、動物細胞培養液をそれぞれ独立に構成要
素として含む、培養用キット。3. A support, a bone marrow stem cell, and / or a support composed essentially of a composite material in which a biodegradable synthetic polymer is present in a fibrous form in a sponge composed of a crosslinked natural polymer. A culture kit, which contains, as independent components, living tissue cells differentiated from bone marrow stem cells, and / or intermediate cells in the differentiation process, and an animal cell culture medium, respectively, as constituent elements.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002076929A JP4344112B2 (en) | 2002-03-19 | 2002-03-19 | Biological tissue-like structure, bone marrow stem cell culture method and culture kit |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002076929A JP4344112B2 (en) | 2002-03-19 | 2002-03-19 | Biological tissue-like structure, bone marrow stem cell culture method and culture kit |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2003265169A true JP2003265169A (en) | 2003-09-24 |
JP4344112B2 JP4344112B2 (en) | 2009-10-14 |
Family
ID=29205506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002076929A Expired - Fee Related JP4344112B2 (en) | 2002-03-19 | 2002-03-19 | Biological tissue-like structure, bone marrow stem cell culture method and culture kit |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4344112B2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006088029A1 (en) * | 2005-02-15 | 2006-08-24 | School Juridical Person Kitasato Gakuen | Method of producing high-density cultured tissue and high-density cultured tissue |
JP2009508540A (en) * | 2005-08-17 | 2009-03-05 | オックスフォード バイオマテリアリルズ リミテッド | Implantable cartilage repair device |
WO2010016469A1 (en) * | 2008-08-04 | 2010-02-11 | 片山化学工業株式会社 | Technique for regulating regeneration of tissue or faulty or abnormal part in organ using nell-1 |
JP2014014697A (en) * | 2008-11-14 | 2014-01-30 | Tokyo Univ Of Agriculture & Technology | Method for manufacturing artificial blood vessel |
JP2015164645A (en) * | 2005-05-04 | 2015-09-17 | シンセス ゲゼルシャフト ミット ベシュレンクテル ハフツングSynthes Gmbh | coupling member |
US10660638B2 (en) | 2012-03-01 | 2020-05-26 | DePuy Synthes Products, Inc. | Surgical suture with soft core |
CN116350852A (en) * | 2022-11-17 | 2023-06-30 | 上海市伤骨科研究所 | Fiber sponge scaffold with improved mechanical properties and multi-site capture of copper ions and its preparation method |
-
2002
- 2002-03-19 JP JP2002076929A patent/JP4344112B2/en not_active Expired - Fee Related
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006088029A1 (en) * | 2005-02-15 | 2006-08-24 | School Juridical Person Kitasato Gakuen | Method of producing high-density cultured tissue and high-density cultured tissue |
US9757120B2 (en) | 2005-05-04 | 2017-09-12 | DePuy Synthes Products, Inc. | Joining element |
US12268384B2 (en) | 2005-05-04 | 2025-04-08 | DePuy Synthes Products, Inc. | Joining element |
US11471154B2 (en) | 2005-05-04 | 2022-10-18 | DePuy Synthes Products, Inc. | Joining element |
US10542972B2 (en) | 2005-05-04 | 2020-01-28 | DePuy Synthes Products, Inc. | Joining element |
US9757121B2 (en) | 2005-05-04 | 2017-09-12 | DePuy Synthes Products, Inc. | Joining element |
JP2015164645A (en) * | 2005-05-04 | 2015-09-17 | シンセス ゲゼルシャフト ミット ベシュレンクテル ハフツングSynthes Gmbh | coupling member |
US9226992B2 (en) | 2005-08-17 | 2016-01-05 | Orthox Limited | Implantable cartilaginous tissue repair device |
JP2009508540A (en) * | 2005-08-17 | 2009-03-05 | オックスフォード バイオマテリアリルズ リミテッド | Implantable cartilage repair device |
JP5641477B2 (en) * | 2008-08-04 | 2014-12-17 | 学校法人昭和大学 | Tissue / organ ectopic regeneration control technology by NELL-1 |
WO2010016469A1 (en) * | 2008-08-04 | 2010-02-11 | 片山化学工業株式会社 | Technique for regulating regeneration of tissue or faulty or abnormal part in organ using nell-1 |
JP2014014697A (en) * | 2008-11-14 | 2014-01-30 | Tokyo Univ Of Agriculture & Technology | Method for manufacturing artificial blood vessel |
US10660638B2 (en) | 2012-03-01 | 2020-05-26 | DePuy Synthes Products, Inc. | Surgical suture with soft core |
CN116350852A (en) * | 2022-11-17 | 2023-06-30 | 上海市伤骨科研究所 | Fiber sponge scaffold with improved mechanical properties and multi-site capture of copper ions and its preparation method |
Also Published As
Publication number | Publication date |
---|---|
JP4344112B2 (en) | 2009-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Huang et al. | 3D printed gelatin/hydroxyapatite scaffolds for stem cell chondrogenic differentiation and articular cartilage repair | |
Li et al. | Periosteum tissue engineering—a review | |
Ikada | Tissue engineering: fundamentals and applications | |
US6662805B2 (en) | Method for composite cell-based implants | |
US8968401B2 (en) | Synthetic scaffolds and organ and tissue transplantation | |
US20090214614A1 (en) | Method for Cell Implantation | |
Cho et al. | Chitosan gel as an in situ–forming scaffold for rat bone marrow mesenchymal stem cells in vivo | |
Nakayama | In vitro biofabrication of tissues and organs | |
MX2012008215A (en) | Bioengineered tissue constructs and methods for producing and using thereof. | |
JP2021102054A (en) | Powder composition for generating cross-linked protein foam and method for using the same | |
JPH04505717A (en) | In vivo cartilage generation from cell cultures | |
Zhang et al. | A study on a tissue-engineered bone using rhBMP-2 induced periosteal cells with a porous nano-hydroxyapatite/collagen/poly (L-lactic acid) scaffold | |
JP4344112B2 (en) | Biological tissue-like structure, bone marrow stem cell culture method and culture kit | |
JP2004283371A (en) | Medical material | |
JP2014524269A (en) | Self-transplantation system preparation method and transplantation system obtained thereby | |
Bharti et al. | Biomaterials and Scaffolds in Stem Cell Therapy | |
WO2022156648A1 (en) | Ear cartilage tissue engineering complex and use thereof | |
RU2822238C1 (en) | Graft-tissue-engineered perichondrium for cartilage restoration of subject | |
RU2807692C2 (en) | Method for obtaining tissue-engineered perichondrium transplant based on cell spheroids | |
CA2682453C (en) | Method for obtaining three-dimensional structures for tissue engineering | |
Takagi | Scaffold-based tissue engineering | |
JP2024523931A (en) | Method for hardening alginate/gelatin hydrogels | |
Jian et al. | Modified acellular dermal matrix for chondrocyte implantation in repairing cartilage defects of rabbits○ | |
Zhang | Preparation of Porous Scaffolds with Controlled Pore Structures for Tissue Engineering | |
Brown | Tissue Engineering Applications for Burn Wounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041216 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20070124 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080205 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080404 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080507 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080704 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090707 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090710 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120717 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4344112 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120717 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120717 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150717 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |